Vor Biopharma (NASDAQ:VOR) Shares Up 9.3% – Here’s Why

Vor Biopharma Inc. (NASDAQ:VOR)’s share price shot up 9.3% during trading on Thursday . The stock traded as high as $14.73 and last traded at $14.6950. 260,078 shares traded hands during trading, a decline of 73% from the average session volume of 965,606 shares. The stock had previously closed at $13.44.

Analyst Upgrades and Downgrades

Several research firms recently commented on VOR. HC Wainwright restated a “buy” rating and set a $31.00 target price on shares of Vor Biopharma in a research report on Monday, May 18th. Weiss Ratings restated a “sell (d-)” rating on shares of Vor Biopharma in a research report on Monday. Jefferies Financial Group upgraded shares of Vor Biopharma to a “strong-buy” rating in a research note on Thursday, April 30th. Wells Fargo & Company began coverage on shares of Vor Biopharma in a research note on Thursday, March 19th. They issued an “overweight” rating and a $30.00 target price for the company. Finally, Wedbush lifted their target price on shares of Vor Biopharma from $15.00 to $18.00 and gave the company a “neutral” rating in a research note on Thursday, May 14th. Two investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $42.25.

Vor Biopharma Stock Up 6.5%

The business has a fifty day moving average of $15.24 and a 200 day moving average of $13.69.

Vor Biopharma (NASDAQ:VOR) last announced its earnings results on Monday, March 30th. The company reported $307.61 earnings per share for the quarter. On average, equities analysts expect that Vor Biopharma Inc. will post -2.51 EPS for the current fiscal year.

Insider Activity

In other news, Director Ra Capital Management, L.P. sold 165,150 shares of the firm’s stock in a transaction that occurred on Wednesday, April 22nd. The stock was sold at an average price of $15.77, for a total value of $2,604,415.50. Following the completion of the sale, the director directly owned 2,402,095 shares of the company’s stock, valued at $37,881,038.15. This trade represents a 6.43% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders sold 3,002,903 shares of company stock valued at $49,412,176 over the last ninety days. Company insiders own 0.27% of the company’s stock.

Hedge Funds Weigh In On Vor Biopharma

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. China Universal Asset Management Co. Ltd. bought a new position in shares of Vor Biopharma in the 4th quarter valued at $36,000. Goldman Sachs Group Inc. boosted its position in shares of Vor Biopharma by 218.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock valued at $61,000 after purchasing an additional 58,247 shares in the last quarter. XTX Topco Ltd bought a new stake in shares of Vor Biopharma during the 2nd quarter valued at about $66,000. Chung Wu Investment Group LLC bought a new position in Vor Biopharma in the fourth quarter worth approximately $109,000. Finally, Susquehanna Portfolio Strategies LLC purchased a new stake in shares of Vor Biopharma in the fourth quarter worth approximately $134,000. 97.29% of the stock is owned by institutional investors and hedge funds.

About Vor Biopharma

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).